Report Previews Future of U.S. Biosimilar Market - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Report Previews Future of U.S. Biosimilar Market


The IP & Science business of Thomson Reuters released a life sciences report, “An Outlook on U.S. Biosimilar Competition,” which provides a view of the challenges facing companies entering the United States biosimilar drug market and key players predicted to break into this developing pharmaceutical space.

While the US continues to take steps toward entering the global biosimilar market, it lags behind other nations in this space, the report says. The report compares US and EU regulations to underscore the significant differences between these regions and explore ways the US can compete more effectively, in addition to reviewing emerging regulatory developments in India and China. It also identifies potential leaders of the US market, including Amgen, Hospira, and Sandoz, among the top pharmaceutical companies with the most potential to dominate the early stages of biosimilar medications entering the US.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here